Área Oncología

Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Andrés Cervantes Ruipérez

El Dr. Andrés Cervantes es Profesor Titular de Medicina en la Universidad de Valencia desde 1991. Su formación como Médico Interno Residente la llevó a cabo en el Hospital Clínico Universitario de Valencia. Tras completar este periodo consiguió una beca predoctoral en la Free University Hospital en Amsterdam, donde obtuvo su Doctorado en el laboratorio de farmacología celular, con un trabajo sobre la resistencia a múltiples fármacos. 

El Dr. Cervantes es Jefe de Servicio de Oncología Médica en el Hospital Clínico Universitario de Valencia.  También es director del Área de Cáncer en el Instituto de Investigación Sanitaria – INCLIVA. Sus principales áreas de interés e investigación son cáncer gastrointestinal y ginecológico, así como ensayos fase I y de desarrollo de nuevos fármacos. Es investigador clínico de cáncer rectal, un tema en el que ha desarrollado varias publicaciones sobre la calidad del trabajo multidisciplinar así como la evaluación de la calidad de la cirugía mesorrectal, cómo optimizar la elección idónea de la terapia inicial y, especialmente, cómo tratar el cáncer del tercio superior del recto. Es autor de más de 300 artículos y revisiones de trabajos publicados en diferentes revistas. Es también Editor de la revista Cancer Treatment Reviews. Es Presidente del Educational Steering Committee de ESMO (Sociedad Europea de Oncología Médica) y desde enero de 2014 también es Editor asociado, en la sección de cáncer gastrointestinal, en la revista de Annals of Oncology.

Para más info: http://indest.uv.es/

 

Grupo de Investigación en Cáncer Colorrectal y nuevos Desarrollos Terapéuticos en Tumores Sólidos

Investigador colaborador

Alejandro Espí Macías
Amelia Insa Mollá
Ana Isabel Gil Tébar
Desamparados Roda Pérez
Estefania García Botello
Gema Bruixola Campos
Gloria Ribas Despuig
Jose. A. Pérez Fidalgo
Josefa Castillo Aliaga
Maider Ibarrola Villava
Marcelino Telechea Fernández
María Carolina Martínez Ciarpaglini
Marisol Huerta Álvaro
Marta Llorca Cardeñosa
Noelia Tarazona Llavero
Susana Roselló Keranen

Técnico

Cristina Mongort Sanchis

Administrativo

Gabriela Perez Garity

Data manager

Inma Blasco Blasco
  • Determinar el valor de una serie de marcadores biológicos con interés predictivo pronóstico en pacientes con carcinoma de recto localmente avanzado que han sido tratados en ensayos clínicos.
  • Establecer el papel de las proteínas acetiladas en el desarrollo de resistencia al tratamiento con fármacos con efecto anti-EGFR, tanto en tumores mutados como en ausencia de mutaciones KRAS.
  • Desarrollar la asociación terapéutica entre inhibidores de m-TOR y anticuerpos que bloquean IGFR-1.
  • Validar la administración de siRNAs como agentes antitumorales en pacientes con metástasis hepáticas.
  • Determinar las dosis recomendadas para el tratamiento de pacientes con tumores avanzados de fármacos dirigidos contra dianas moleculares solos o en combinación con quimioterapia o con otros agentes biológicos.
Número total de publicaciones: 209. Factor de Impacto acumulado: 1484.38
Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results.
Flor-Lorente B, Báguena G, Frasson M, García-Granero A, Cervantes A, Sanchiz V, Peña A, Espí A, Esclapez P, García-Granero E.
Cirugía española. 2017 Mar. 143-151. FI: 1.276
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A.
The Lancet. Oncology. 2017 Apr. 545-554. FI: 33.9
The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit.
2015 European Society of Coloproctology collaborating group.
Colorectal disease. 2017 Mar 6. . FI: 2.689
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 10. JCO2017730143. FI: 24.008
Laparoscopy may decrease morbidity and length of stay after elective colon cancer resection, especially in frail patients: results from an observational real-life study.
Cerdán Santacruz C, Frasson M, Flor-Lorente B, Ramos Rodríguez JL, Trallero Anoro M, Millán Scheiding M, Maseda Díaz O, Dujovne Lindenbaum P, Monzón Abad A, García-Granero Ximenez E, ANACO Study Group.
Surgical endoscopy. 2017 Apr 28. . FI: 3.747
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.
PloS one. 2017. e0177331. FI: 2.806
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials.
Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F.
ESMO open. 2017 Apr 12.
Controversies in the multimodality management of locally advanced rectal cancer.
Díaz Beveridge R, Akhoundova D, Bruixola G, Aparicio J.
Medical oncology.. 2017 Jun. 102. FI: 2.634
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.
Clinical lung cancer. 2017 Mar. 178-188.e4. FI: 3.434
Is It a Metastatic Disease: A Case Report and New Understanding of Rosai-Dorfman Disease?
Martínez-Ciarpaglini C, Monteagudo C.
The American Journal of dermatopathology. 2017 Nov. 0193-1091. FI: 1.095
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.
Cancer discovery. 2017 Jan. 102-113. FI: 20.011
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R.
Clinical & translational oncology. 2017 Feb. 227-235. FI: 2.353
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien ME, Yap TA.
European journal of cancer. 2017 Apr. 56-62. FI: 6.029
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL.
Cell metabolism. 2017 Oct. 633-47. FI: 18.164
Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
Tarazona N, Cervantes A.
Annals of oncology. 2017 Oct. . FI: 11.855
A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers
Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates JW, Schellens JHM.
Clinical cancer research. 2017 Oct. . FI: 9.619
Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection An international audit by ESCP and S-ECCO
2015 European Society of Coloproctology collaborating group.
Colorectal disease. 2017 Sep 15. 1462-8910. FI: 2.689
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I.
British journal of cancer. 2017 Nov. 1478-85. FI: 6.176
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
Clinical & translational oncology. 2017 Sep 20. 1699-048X. FI: 2.353
mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival
García-García AB#1,2, Gómez-Mateo MC#3,4, Hilario R2, Rentero-Garrido P2, Martínez-Domenech A5, Gonzalez-Albert V2, Cervantes A6, Marín-Garcia P7, Chaves FJ1,2, Ferrández-Izquierdo A3, Sabater L5.
Oncotarget. 2017 Aug 3. 104796-104805. FI: 5.168
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
Jordan K, Aapro M, Kaasa S, Ripamonti C, Scotté F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, Cervantes A.
Annals of oncology. 2017 Dec 14. . FI: 34.424
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.. 2017 Apr. 752-762. FI: 6.595
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.
Annals of oncology. 2017 Nov 16. 0923-7534. FI: 11.855
Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score
Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, Cervantes A.
Clinical colorectal cancer. 2017 Oct 28. 1533-0028. FI: 4.507
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, PETACC8 Study Investigators., Austrian Breast and Colorectal cancer Study Group (ABCSG)., Belgian Group of Digestive Oncology (BGDO)., Lone Nørgård Petersen., Fédération Francophone de Cancérologie Digestive (FFCD)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO)., Arbeitsgemeinschaft Internistische Onkologie (AIO)., Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD)., Gruppo Oncologico dell'Italia Meridionale (GOIM)., Istituto Oncologico Romagnolo (IOR)., Gruppo Cooperativo Chirurgico Italiano (GOCCI)., Gruppo Oncologico Nord Ovest (GONO)., Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)., Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO)., Grupo Español para el Tratamiento de los Tumores Digestivos (TTD)., John Allen Bridgewater.
European journal of cancer. 2017 Sep. 16-24. FI: 6.029
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.
Lung cancer : journal of the International Association for the Study of Lung Cancer.. 2017 Jun. 154-160. FI: 4.294
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martorell PM, Huerta M, Quilis AC, Abellán R, Seda E, Blesa S, Chaves FJ, Beltrán DD, Keränen SR, Franco J, Insa A.
Clinical lung cancer. 2017 Apr 27. . FI: 3.434
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.
The oncologist. 2017 Jun 7. . FI: 4.962
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity.
Meulendijks D, Jacob W, Voest EE, Mau-Sørensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema M, Langenberg MH, de Jonge MJA, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Harring SV, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen U.
Clinical cancer research. 2017 Jun 9. . FI: 9.619
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
Clinical & translational oncology. 2017 Aug 16. 1699-048X. FI: 2.353
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F.
ESMO open. 2017 Jan 16. 2059-7029
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee.
Annals of oncology. 2017 Jul 1. 0923-7534. FI: 11.855
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines
Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K; ESMO Guidelines Committee.
Annals of oncology. 2017 Jul 1. 0923-7534. FI: 11.855
Individual surgeon is an independent risk factor for leak after double-stapled colorectal anastomosis: An institutional analysis of 800 patients.
García-Granero E, Navarro F, Cerdán Santacruz C, Frasson M, García-Granero A, Marinello F, Flor-Lorente B, Espí A.
Surgery. 2017 Jul 21. . FI: 3.904
In the literature: April 2017.
Cervantes A.
ESMO open. 2017. e000193
In the literature: February 2017.
Cervantes A, Terol MJ.
ESMO open. 2017. e000171
Magnetic resonance defecography versus videodefecography in the study of obstructed defecation syndrome: Is videodefecography still the test of choice after 50 years?
Martín-Martín GP, García-Armengol J, Roig-Vila JV, Espí-Macías A, Martínez-Sanjuán V, Mínguez-Pérez M, Lorenzo-Liñán MÁ, Mulas-Fernández C, González-Argenté FX.
Techniques in coloproctology. 2017 Oct. 1123-6337. FI: 2.342
Genetic 3'UTR variation is associated with human pigmentation characteristics and sensitivity to sunlight.
Hernando B, Peña-Chilet M, Ibarrola-Villava M, Martin-Gonzalez M, Gomez-Fernandez C, Ribas G, Martinez-Cadenas C
Experimental dermatology.. 2017 Mar 7. . FI: 2.675
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A
Oncotarget. 2016 Apr 19. 22543-55. FI: 5.168
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.
Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget. 2016 Sep 27. 63424-63436. FI: 5.168
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.
Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T
Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.. 2016 Aug 20. . FI: 2.719
Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin.
Hernando B, Ibarrola-Villava M, Fernandez LP, Peña-Chilet M, Llorca-Cardeñosa M, Oltra SS, Alonso S, Boyano MD, Martinez-Cadenas C, Ribas G
Biology of sex differences. 2016. 17. FI: 4.837
Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
Cherny NI, Kloke M, Cervantes A, Pentheroudakis G, ESMO Guidelines Committee
Annals of oncology: official journal of the European Society for Medical Oncology. 2016 Mar. 550-1. FI: 7.04
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D, Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Treatment of Cancer—Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario (GEICO)
Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer.. 2016 Mar. 1241-9. FI: 2.364
Risk factors for anastomotic leak and postoperative morbidity and mortality after elective right colectomy for cancer: results from a prospective, multicentric study of 1102 patients.
Frasson M, Granero-Castro P, Ramos Rodríguez JL, Flor-Lorente B, Braithwaite M, Martí Martínez E, Álvarez Pérez JA, Codina Cazador A, Espí A, Garcia-Granero E, ANACO Study Group
International journal of colorectal disease.. 2016 Jan. 105-14. FI: 2.449
Sequence Variation in Mature MicroRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N
Carcinogenesis.. 2016 Jul 5. . FI: 4.874
Association of Melanocortin-1 receptor variants with pigmentary traits in humans: a pooled analysis from the m-skip project.
Tagliabue E, Gandini S, García-Borrón JC, Maisonneuve P, Newton-Bishop J, Polsky D, Lazovich D, Kumar R, Ghiorzo P, Ferrucci L, Gruis NA, Puig S, Kanetsky PA, Motokawa T, Ribas G, Landi MT, Fargnoli MC, Wong TH, Stratigos A, Helsing P, Guida G, Autier P, Han J, Little J, Sera F, Raimondi S, M-SKIP Study group.
The Journal of investigative dermatology.. 2016 Sep. 1914-7. FI: 6.915
Treatment sequence of synchronously (liver) metastasized colon cancer.
Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E
Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.. 2016 Jun 17. . FI: 2.719
Sex and MC1R variants in human pigmentation: Differences in tanning ability and sensitivity to sunlight between sexes.
Hernando B, Ibarrola-Villava M, Peña-Chilet M, Alonso S, Ribas G, Martinez-Cadenas C
Journal of dermatological science. Supplement.. 2016 Dec. 346-348. FI: 3.739
Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.
Breugom AJ, Bastiaannet E, Boelens PG, Iversen LH, Martling A, Johansson R, Evans T, Lawton S, O'Brien KM, Van Eycken E, Janciauskiene R, Liefers GJ, Cervantes A, Lemmens VE, van de Velde CJ
European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 2016 Jun 11. 110-117. FI: 6.163
Anastomotic leakage after colon cancer resection: does the individual surgeon matter?
Marinello FG, Baguena G, Lucas E, Frasson M, Hervás D, Flor-Lorente B, Esclapez P, Espí A, García-Granero E
Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland.. 2016 Jun. 562-9. FI: 2.351
Assessing PTEN Subcellular Localization.
Gil A, López JI, Pulido R
Photosynthesis research protocols. 2016. 169-86
Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
Gambardella V, Tarazona N, Cejalvo JM, Roselló S, Cervantes A
Expert opinion on drug metabolism & toxicology.. 2016 Apr. 449-56. FI: 2.831
Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.
Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D
Therapeutic advances in medical oncology.. 2016 Mar. 104-12. FI: 2.827
Erratum to «Non-surgical treatment of localized rectal cancer is an experimental option».
Roselló S, Cervantes A
Cirugía española.. 2016 Sep 22. . FI: 1
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D
Annals of oncology: official journal of the European Society for Medical Oncology. 2016 Jul 5. . FI: 9.269
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group.
ESMO open.. 2016 Aug. 1378-81. FI: 9.269
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I
Clinical colorectal cancer.. 2016 Jun. e53-9. FI: 2.813
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN
Clinical cancer research: an official journal of the American Association for Cancer Research.. 2016 Feb 15. 877-85. FI: 8.722
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, ESMO Guidelines Committee
ESMO open.. 2016 Sep. v38-v49. FI: 9.269
High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial.
Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SR, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC
Cancer discovery.. 2016 May 13. . FI: 19.453
MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.
Fleitas T, Ibarrola-Villava M, Ribas G, Cervantes A
Cancer treatment reviews.. 2016 Jul 29. 57-64. FI: 7.983
Non-surgical treatment of localized rectal cancer is an experimental option.
Roselló S, Cervantes A
Cirugía española.. 2016 Apr 26. . FI: 0.743
PAN-EX: A pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I
Annals of oncology: official journal of the European Society for Medical Oncology. 2016 May 23. . FI: 7.04
Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N, Gambardella V, Huerta M, Roselló S, Cervantes A
Current oncology reports.. 2016 Jul. 41. FI: 2.891
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J
British journal of cancer.. 2016 Feb 16. 372-80. FI: 4.836
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Reynés G, Martínez-Sales V, Vila V, Balañá C, Pérez-Segura P, Vaz MA, Benavides M, Gallego O, Palomero I, Gil-Gil M, Fleitas T, Reche E
Anti-cancer drugs.. 2016 Feb. 133-7. FI: 1.784
Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: one size does not fit all.
Cervantes A, Glynne-Jones R
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Apr. 617-9. FI: 7.04
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD, LUX-Lung 8 Investigators
The Lancet. Oncology.. 2015 Aug. 897-907. FI: 24.69
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD
Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015 Dec 15. 5469-79. FI: 8.722
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N, Mayo-de Las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R, Spanish Lung Cancer Group
JAMA oncology. 2015 May 1. 149-57
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v56-68. FI: 7.04
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v69-77. FI: 7.04
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v133-8. FI: 7.04
Central venous access in oncology: ESMO Clinical Practice Guidelines.
Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D, Cardoso F, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v152-68. FI: 7.04
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v78-84. FI: 7.04
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial.
Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1. 49-59. FI: 8.722
Critical evaluation of the scientific content in clinical practice guidelines.
Cervantes A, Pentheroudakis G, Arnold D
Cancer cytopathology.. 2015 Jun 1. 1907-8. FI: 4.889
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v126-32. FI: 7.04
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.
Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A
Oncotarget. 2015 Sep 29. 26935-45. FI: 6.359
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v116-25. FI: 7.04
EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá R
PloS one. 2015. e0130543. FI: 3.234
Extending neoadjuvant chemotherapy in rectal cancer.
Roselló S, Cervantes A
The Lancet. Oncology. 2015 Aug. 880-1. FI: 24.69
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S
Gut. 2015 Jun. 921-8. FI: 14.66
Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.
Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf D, Martin-Gonzalez M, Mayor M, Grandchamp B, Ribas G, Soufir N
International journal of cancer. Journal international du cancer. 2015 May 1. 2109-19. FI: 5.085
Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v100-7. FI: 7.04
Heterogeneity of driver genes and therapeutic implications in colorectal cancer.
Dienstmann R, Cervantes A
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Aug. 1523-5. FI: 7.04
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U
Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015 Apr 15. 1869-76. FI: 8.722
Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.
Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, Teruel A, Lluch A, Chirivella I
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015 Feb. 167-72. FI: 2.077
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v31-9. FI: 7.04
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.
Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v139-51. FI: 7.04
MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.
Tagliabue E, Fargnoli MC, Gandini S, Maisonneuve P, Liu F, Kayser M, Nijsten T, Han J, Kumar R, Gruis NA, Ferrucci L, Branicki W, Dwyer T, Blizzard L, Helsing P, Autier P, García-Borrón JC, Kanetsky PA, Landi MT, Little J, Newton-Bishop J, Sera F, Raimondi S, M-SKIP Study Group
British journal of cancer.. 2015 Jul 14. 354-63. FI: 4.836
MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, Chirivella E, Climent J, Lluch A, Eroles P
Journal of Cellular Biochemistry. 2015 Sep. 2061-73. FI: 3.446
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators
The New England journal of medicine. 2015 May 21. 2018-28. FI: 55.873
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v108-15. FI: 7.04
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F
British journal of cancer.. 2015 Jun 9. 1874-81. FI: 4.836
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v85-99. FI: 7.04
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v8-30. FI: 7.04
Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.
Tarazona N, Navarro L, Cejalvo JM, Gambardella V, Pérez-Fidalgo JA, Sempere A, Navarro S, Cervantes A
OncoTargets and therapy. 2015. 1053-9. FI: 2.311
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. 1936-41. FI: 7.04
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, RECOURSE Study Group
The New England journal of medicine. 2015 May 14. 1909-19. FI: 55.873
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J
Cancer discovery.. 2015 Jun. 598-609. FI: 19.453
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jun 1. 2462-70. FI: 8.722
Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
Marinello FG, Frasson M, Baguena G, Flor-Lorente B, Cervantes A, Roselló S, Espí A, García-Granero E
Diseases of the colon and rectum. 2015 Jun. 556-65. FI: 3.749
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS
Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015 Oct 15. 4586-96. FI: 8.722
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.
Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas J, Brown G, Oates J, Chau I
International journal of radiation oncology, biology, physics.. 2015 Oct 1. 303-12. FI: 4.258
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators
The Lancet. Oncology.. 2015 Aug. 928-36. FI: 24.69
The ESMO guideline strategy: an identity statement and reflections on improvement.
Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters S, Horwich A, Pavlidis N, Stahel R, Cervantes A, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015 Sep. v1-v7. FI: 7.04
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v40-55. FI: 7.04
Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines.
Kloke M, Cherny N, ESMO Guidelines Committee
Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Sep. v169-73. FI: 7.04
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum.
van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RG, van den Broek CB, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CA, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V
European journal of cancer (Oxford, England : 1990). 2014 Jan. 1.e1-1.e34. FI: 4.819
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Jan. 107-16. FI: 6.578
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).
Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Jan. 42248. FI: 6.578
Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM
Molecular cancer therapeutics. 2014 May. 1382-9. FI: 5.683
Emerging EGFR antagonists for breast cancer.
Lluch A, Eroles P, Perez-Fidalgo JA
Expert opinion on emerging drugs. 2014 Jun. 165-81. FI: 3.058
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC
European journal of cancer (Oxford, England : 1990). 2014 Feb. 496-505. FI: 4.819
Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014 May. 584-91. FI: 2.892
An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer.
Garcia-Carbonero R, Rivera F, Maurel J, Ayoub JP, Moore MJ, Cervantes A, Asmis TR, Schwartz JD, Nasroulah F, Ballal S, Tabernero J
The oncologist. 2014. 350-1. FI: 4.54
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014 Jan. 189-94. FI: 4.857
Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: a prospective study.
Lorenzo MJ, Modesto M, Pérez J, Bollo E, Cordovilla R, Muñoz M, Pérez-Fidalgo JA, Cases E
Palliative medicine. 2014 Apr. 326-34. FI: 2.845
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M
Lung cancer (Amsterdam, Netherlands). 2014 May. 161-7. FI: 3.737
Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk.
Llorca-Cardeñosa MJ, Peña-Chilet M, Mayor M, Gomez-Fernandez C, Casado B, Martin-Gonzalez M, Carretero G, Lluch A, Martinez-Cadenas C, Ibarrola-Villava M, Ribas G
European journal of cancer (Oxford, England : 1990). 2014 Dec. 3168-77. FI: 4.819
Management of cryptoglandular supralevator abscesses in the magnetic resonance imaging era: a case series.
Garcia-Granero A, Granero-Castro P, Frasson M, Flor-Lorente B, Carreño O, Espí A, Puchades I, Garcia-Granero E
International journal of colorectal disease. 2014 Dec. 1557-64. FI: 2.415
Emergence of constitutively active estrogen receptor-? mutations in pretreated advanced estrogen receptor-positive breast cancer.
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA
Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1. 1757-67. FI: 8.193
Exploring better strategies for EGFR antibodies in colon cancer.
Cervantes A
The lancet oncology. 2014 May. 549-50. FI: 24.725
Unmet needs and challenges in gastric cancer: the way forward.
Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A
Cancer treatment reviews. 2014 Jul. 692-700. FI: 6.466
MicroRNA profile in very young women with breast cancer.
Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G
BMC cancer. 2014 Jul 21. 529. FI: 3.362
Crizotinib and renal insufficiency: A case report and review of the literature.
Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, Insa Molla A
Lung cancer (Amsterdam, Netherlands). 2014 Jun. 310-3. FI: 3.737
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.
Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F
Medical oncology (Northwood, London, England). 2014 Aug. 76. FI: 2.058
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii10-20. FI: 6.578
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii1-iii9. FI: 6.578
Multicenter study of outcome in relation to the type of resection in rectal cancer.
Ortiz H, Wibe A, Ciga MA, Kreisler E, Garcia-Granero E, Roig JV, Biondo S, Spanish Rectal Cancer Project
Diseases of the colon and rectum. 2014 Jul. 811-22. FI: 3.198
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel R
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. 1673-8. FI: 6.578
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.
Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014 Jun. 330-9. FI: 4.857
Age differences in presentation, diagnosis pathway and management of colorectal cancer.
Esteva M, Ruiz A, Ramos M, Casamitjana M, Sánchez-Calavera MA, González-Luján L, Pita-Fernández S, Leiva A, Pértega-Díaz S, Costa-Alcaraz AM, Macià F, Espí A, Segura JM, Lafita S, Novella MT, Yus C, Oliván B, Cabeza E, Seoane-Pillado T, López-Calviño B, Llobera J, DECCIRE GROUP
Cancer epidemiology. 2014 Aug. 346-53. FI: 2.558
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014 Sep. 814-22. FI: 1.6
Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.
Stoyianni A, Pentheroudakis G, Benjamin H, Cervantes A, Ashkenazi K, Lazaridis G, Pavlidis N, Spector Y
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014 Aug. 725-31. FI: 1.6
Quality assurance in the treatment of colorectal cancer: the EURECCA initiative.
Breugom AJ, Boelens PG, van den Broek CB, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJ
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Aug. 1485-92. FI: 6.578
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.
Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I
Journal of the National Cancer Institute. 2014 Jul. . FI: 15.161
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N
Clinical & experimental metastasis. 2014 Oct. 761-9. FI: 3.725
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.
Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014 Oct. 1165-76. FI: 2.892
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii83-92. FI: 6.578
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii49-56. FI: 6.578
ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation.
Cherny NI, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii143-52. FI: 6.578
ESMO Clinical Practice Guidelines on palliative care: advanced care planning.
Schrijvers D, Cherny NI, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii138-42. FI: 6.578
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii70-5. FI: 6.578
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fenaux P, Haase D, Sanz GF, Santini V, Buske C, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii57-69. FI: 6.578
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii76-82. FI: 6.578
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii27-39. FI: 6.578
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii40-8. FI: 6.578
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii93-101. FI: 6.578
Bone health in cancer patients: ESMO Clinical Practice Guidelines.
Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Sep. iii124-37. FI: 6.578
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators
The lancet oncology. 2014 Jul. 862-73. FI: 24.725
Subcutaneous trastuzumab: drug development and current position.
Martín Martorell P, Bermejo de Las Heras B, Pérez-Fidalgo JA, Huerta Alvaro M, Martín M, Albanell J, Lluch Hernández A
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014 Oct. 859-64. FI: 1.6
Strategies for modern biomarker and drug development in oncology.
Smith AD, Roda D, Yap TA
Journal of hematology & oncology. 2014 Oct 3. 70. FI: 4.933
Prognostic implications of the standardized study of resection margins in pancreatic cancers.
Sabater L, Gómez-Mateo MD, López-Sebastián J, Muñoz-Forner E, Morera-Ocón F, Cervantes A, Roselló S, Camps-Vilata B, Ferrández A, Ortega J
Cirugía española. 2014 Oct. 532-538. FI: 0.89
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.
Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH
Experimental hematology & oncology. 2014. 26
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R, Spanish Lung Cancer Group, French Lung Cancer Group, Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014 Nov. 2147-55. FI: 6.578
Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA
Anti-cancer drugs. 2014 Jan. 42186. FI: 1.891
Anatomical basis for the low incidence of internal hernia after a laparoscopic Roux-en-Y gastric bypass without mesenteric closure.
Ortega J, Cassinello N, Sánchez-Antúnez D, Sebastián C, Martínez-Soriano F
Obesity surgery. 2013 Aug. 1273-80. FI: 3.102
An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.
Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM
Breast (Edinburgh, Scotland). 2013 Oct. 974-9. FI: 2.581
Combined activity of post-exercise concentrations of NA and eHsp72 on human neutrophil function: role of cAMP.
Giraldo E, Hinchado MD, Ortega E
Journal of cellular physiology. 2013 Sep. 1902-6. FI: 4.218
Caries diagnosis: agreement between WHO and ICDAS II criteria in epidemiological surveys.
Iranzo-Cortés JE, Montiel-Company JM, Almerich-Silla JM
Community dental health. 2013 Jun. 108-11. FI: 0.9320000000000001
EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe.
van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer Care
European journal of cancer (Oxford, England : 1990). 2013 Sep. 2784-90. FI: 5.061
Involvement of prostacyclin and potassium channels in the diabetes-induced hyporeactivity of the rabbit carotid artery to B-type natriuretic peptide.
Centeno JM, Marrachelli VG, Miranda L, Castelló-Ruiz M, Burguete MC, Jover-Mengual T, Salom JB, Torregrosa G, Miranda FJ, Alborch E
European journal of pharmacology. 2013 Feb 15. 159-67. FI: 2.592
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Glimelius B, Tiret E, Cervantes A, Arnold D, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Oct. vi81-vi88. FI: 7.384
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Oct. vi64-vi72. FI: 7.384
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Oct. vi57-vi63. FI: 7.384
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Oct. vi51-vi56. FI: 7.384
Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.
Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Oct. vi73-vi80. FI: 7.384
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.
González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, Del Campo JM, Cervantes A, García Y, López-Guerrero JA, Mendiola C, Palacios J, Rubio MJ, Poveda Velasco A
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2013 Jul. 509-25. FI: 1.276
Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.
Pérez-Fidalgo JA, Cervantes A
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Apr. 1129-30. FI: 7.384
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA 3rd
Cancer discovery. 2013 Apr. 406-17. FI: 10.143
Implantable loop recorder allows an etiologic diagnosis in one-third of patients.
Lacunza-Ruiz FJ, Moya-Mitjans A, Martínez-Alday J, Barón-Esquivias G, Ruiz-Granell R, Rivas-Gándara N, González-Enríquez S, Leal-Del-Ojo J, F Arcocha-Torres M, Pérez-Villacastín J, Garcia-Heil N, García-Alberola A
Circulation journal : official journal of the Japanese Circulation Society. 2013 Sep 25. 2535-41. FI: 3.578
Imprints of superfluidity on magnetoelastic quasiperiodic oscillations of soft gamma-ray repeaters.
Gabler M, Cerdá-Durán P, Stergioulas N, Font JA, Müller E
Physical review letters. 2013 Nov 22. 211102. FI: 7.943
Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project.
Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia R, RARECARE WG
Cancer epidemiology. 2013 Dec. 850-6. FI: 2.232
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J, CETLAM Group
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2013 Nov. 2157-64. FI: 10.164
Intravenous iron therapy in patients with heart failure. A double-edged sword.
Lippi G, Sanchis-Gomar F, Cervellin G
International journal of cardiology. 2013 Oct 12. 4863. FI: 5.509
Prospective evaluation of intraoperative peripheral nerve injury in colorectal surgery.
Navarro-Vicente F, García-Granero A, Frasson M, Blanco F, Flor-Lorente B, García-Botello S, García-Granero E
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2012 Mar. 382-5. FI: 2.081
Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the impact on lymph node harvest after colon resection for cancer?
Frasson M, Faus C, Garcia-Granero A, Puga R, Flor-Lorente B, Cervantes A, Navarro S, Garcia-Granero E
Diseases of the colon and rectum. 2012 Feb. 197-204. FI: 3.336
Undergraduate training in oncology: An ESO continuing challenge for medical students.
Pavlidis N, Vermorken JB, Stahel R, Bernier J, Cervantes A, Pentheroudakis G, Audisio RA, Costa A
Surgical oncology. 2012 Mar. 15-21. FI: 2.136
Evaluation of the quality of publications on randomized clinical trials using the consolidated standards of reporting trials (CONSORT) statement guidelines in a spanish tertiary hospital.
Dasí F, Navarro-García MM, Jiménez-Heredia M, Magraner J, Viña JR, Pallardó FV, Cervantes A, Morcillo E
Journal of clinical pharmacology. 2012 Jul. 1106-14. FI: 2.963
Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.
Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfinopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N
Clinical & experimental metastasis. 2012 Aug. 603-14. FI: 3.46
Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.
Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfinopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N
Anticancer research. 2012 Apr. 1273-81. FI: 1.713
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 May 10. 1620-7. FI: 18.038
Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.
Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F, RARECARE Working Group
European journal of cancer (Oxford, England : 1990). 2012 Jan. 159-69. FI: 5.061
Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe.
Mallone S, De Vries E, Guzzo M, Midena E, Verne J, Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, Navarro C, Virgili G, RARECARE WG
European journal of cancer (Oxford, England : 1990). 2012 May. 1167-75. FI: 5.061
Incidence and survival of rare urogenital cancers in Europe.
Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN, RARECARE working group
European journal of cancer (Oxford, England : 1990). 2012 Mar. 456-64. FI: 5.061
Occupational exposures and risk of stomach cancer by histological type.
Santibañez M, Alguacil J, de la Hera MG, Navarrete-Muñoz EM, Llorca J, Aragonés N, Kauppinen T, Vioque J, PANESOES Study Group
Occupational and environmental medicine. 2012 Apr. 268-75. FI: 3.215
Rare cancers of the head and neck area in Europe.
Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L, RARECARE Working Group
European journal of cancer (Oxford, England : 1990). 2012 Apr. 783-96. FI: 5.061
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
The lancet oncology. 2012 Mar. 239-46. FI: 25.117
Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?
Perez-Fidalgo JA, Caballero A, Lluch A
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2012 Aug. 643-4. FI: 2.614
Profiling clinical cancer research across the Atlantic: a review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade.
Pentheroudakis G, Krikelis D, Cervantes A, Vermorken J, Pavlidis N
Cancer treatment reviews. 2012 Oct. 560-5. FI: 6.024
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002.
Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C, RARECARE Working Group
European journal of cancer (Oxford, England : 1990). 2012 Jul. 1417-24. FI: 5.061
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A
Cancer treatment reviews. 2012 Oct. 698-707. FI: 6.024
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making.
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct. 2479-516. FI: 7.384
T4a and t4b colorectal cancer: what does this mean nowadays?
Garcia-Granero E, Frasson M, Pous S, Cervantes A
Diseases of the colon and rectum. 2012 Nov. e367. FI: 3.336
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors
The oncologist. 2012. 15-25. FI: 4.095
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J
Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Sep 1. 4764-74. FI: 7.837
Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.
Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu T, Marselos M, Fountzilas G, Malamou-Mitsi V, Pavlidis N
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct. 2725-30. FI: 7.384
Mortality after surgery in Europe: a 7 day cohort study.
Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A, European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology
Lancet. 2012 Sep 22. 1059-65. FI: 39.06
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Enrique Aranda, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
PloS one. 2012. e47345. FI: 3.73
ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines.
Pavlidis N, Stahel R, Pentheroudakis G, Cervantes A, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct. vii7-10. FI: 7.384
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.
Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F, ESMO Guidelines Working Group
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct. vii167-73. FI: 7.384
Carcinoma of endocrine organs: results of the RARECARE project.
van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP, RARECARE WG
European journal of cancer (Oxford, England : 1990). 2012 Sep. 1923-31. FI: 5.061
Quantifying the extent of fistulotomy. How much sphincter can we safely divide? A three-dimensional endosonographic study.
Garcés-Albir M, García-Botello SA, Esclapez-Valero P, Sanahuja-Santafé A, Raga-Vázquez J, Espi-Macías A, Ortega-Serrano J
International journal of colorectal disease. 2012 Aug. 1109-16. FI: 2.238
Dally and Notum regulate the switch between low and high level Hedgehog pathway signalling.
Ayers KL, Mteirek R, Cervantes A, Lavenant-Staccini L, Thérond PP, Gallet A
Development (Cambridge, England). 2012 Sep. 3168-79. FI: 6.208
Preoperative chemotherapy for colon cancer is getting closer.
Cervantes A
The lancet oncology. 2012 Nov. 1073-4. FI: 25.117
Current status of research in breast cancer screening in Spain: implications for prevention.
Sala M, Salas D, Zubizarreta R, Ascunce N, Rué M, Castells X, en nombre de los grupos de investigación RAFP e INCA
Gaceta sanitaria / S.E.S.P.A.S. 2012 Nov-Dec. 574-81. FI: 1.116

Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral.

Referencia:
PI15/02180
Investigador principal:
Andrés Cervantes Ruipérez
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2016 - 31/12/2018
Presupuesto total:
€80.465

INTRACOLOR - Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy

Referencia:
IntraColor
Entidad financiadora:
European Commission e ISCIII (TRANSCAN)
Duración:
01/01/2016 - 31/12/2018
Presupuesto total:
€1.026.927

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)

Referencia:
635342 - MoTriColor
Entidad financiadora:
Comisión Europea
Duración:
01/01/2015 - 31/12/2019
Presupuesto total:
€5.996.992

Clinical Research and Trials Platform

Referencia:
PT13/0002/0031
Investigador principal:
Andrés Cervantes Ruipérez
Entidad financiadora:
Instituto de Salud Carlos III
Duración:
01/01/2014 - 31/12/2014
Presupuesto total:
€65.550

Mecanismos de resistencia inhibidores de EGFR. Estudio epigenómico y de acetilación de proteínas en líneas celulares Kras mutado y salvaje, y su evaluación en pacientes con cáncer de colon

Referencia:
ACOMP/2012/069
Investigador principal:
Andrés Cervantes Ruipérez
Entidad financiadora:
Generalitat Valenciana. Conselleria d'Educació Cultura i Esport
Duración:
30/01/2012 - 30/09/2012
Presupuesto total:
€13.000

Ensayo fase III multicéntrico randomizado de radioterapia de curso corto seguido de quimioterapia preoperatoria prolongada y cirugía en cáncer de recto localizado de alto preoperatoria riesgo frente a quimioradioterapia estándar

Referencia:
EC11-243
Investigador principal:
Andrés Cervantes Ruipérez
Entidad financiadora:
Ministerio de Sanidad y Consumo
Duración:
01/01/2012 - 22/10/2012
Presupuesto total:
€32.451

Genotipado masivo para la caracterización genética de pacientes con melanoma cutáneo esporádico en población española.

Referencia:
SAF2009-07072
Investigador principal:
Gloria Ribas Despuig
Entidad financiadora:
Ministerio de Educación y Ciencia
Duración:
01/01/2010 - 31/12/2012
Presupuesto total:
€35.000

El Hospital Clínico de Valencia e Incliva comparten su experiencia con oncólogos latinoamericanos

Segunda edición PANTUMOR, con el objetivo de intercambiar el conocimiento y “Kow-how” adquirido con otros Hospitales y Centros de Investigación de Latinoamérica

Publicado el 08/03/2018.Leer más »

INCLIVA celebra el Día la Mujer y la Niña en Ciencia con charlas en colegios valencianos

Investigación sanitaria con perspectiva de género 

Publicado el 07/02/2018.Leer más »

Resultados esperanzadores para tratar el cáncer de mama y ginecológico derivado de la mutación AKT1

Confirman por primera vez la eficacia y seguridad del medicamento AZD5363 en humanos.

Publicado el 03/12/2017.Leer más »

INCLIVA recibe la tercera reunión anual del proyecto europeo MOTRICOLOR

Durante dos días se han reunido en INCLIVA los diferentes miembros del consorcio del proyecto europeo

Publicado el 10/11/2017.Leer más »

Alejandro Pérez-Fidalgo participa en la redacción de una guía europea sobre seguridad en la quimioterapia

La guía también ha servido para seguir investigando sobre otros aspectos relacionados con la toxicidad de algunos tratamientos contra el cáncer.

 

Publicado el 28/10/2017.Leer más »

Andrés Cervantes dirige el Preceptorship ESMO en cáncer gástrico en Valencia

Asisten 60 oncólogos procedentes de 20 países.

Publicado el 06/10/2017.Leer más »

Presentación de la cuarta marcha solidaria contra el cáncer de mama "Un Paseo por la Vida, Castellón 2017"

Los fondos se destinarán a sendos proyectos de investigación el Instituto de Investigación Sanitaria INCLIVA y el Hospital provincial de Castellón.

Publicado el 19/09/2017.Leer más »

Noelia Tarazona presenta los proyectos de cáncer colorrectal de INCLIVA en Pobla de Vallbona

Noelia Tarazona, realizó este lunes en Pobla de Vallbona, una charla informativa en cáncer colorrectal.

Publicado el 03/08/2017.Leer más »

Un proyecto de INCLIVA, ganador del premio investigación de la Fundación MERCK SERONO 2017 en Cáncer Colorrectal

Andrés Cervantes Ruipérez recibe el premio de investigación de la Fundación MERCK 2017, en el área de Cáncer Colorrectal.

Publicado el 22/06/2017.Leer más »

Andrés Cervantes inaugura el “Preceptorship en cáncer colorrectal” organizado por la Sociedad Europea de Oncología en Valencia

Valencia recibe hoy y mañana la visita de responsables y jefes de servicio de Oncología europeos en el marco de la jornada “Preceptorship en cáncer colorrectal”, organizada por ESMO, bajo la dirección del profesor Andrés Cervantes.

Publicado el 11/05/2017.Leer más »

INCLIVA y el Hospital Clínico de Valencia lideran un proyecto internacional con Paraguay para desarrollar una estrategia terapéutica personalizada en pacientes con tumores sólidos

INCLIVA y varios centros de investigación médica paraguayos coordinados por el Consejo Nacional de Tecnología y Ciencia de Paraguay han iniciado la puesta en marcha de un proyecto multicéntrico de determinación del perfil mutacional de pacientes con cáncer de tumores sólidos para guiar la estrategia terapéutica hacia una medicina personalizada.

Publicado el 03/05/2017.Leer más »

La Unidad de Ensayos Clínicos Fase I del Hospital Clínico-INCLIVA cerró el 2016 con 26 ensayos con medicamentos oncológicos

Más de 500 pacientes han participado en estos ensayos clínicos oncológicos, donde se prueba por primera vez en humanos la eficacia de un medicamento. En los últimos 4 años, la actividad en estos ensayos se ha duplicado, pasando de los 12 ensayos en 2012 a 26 ensayos en 2016.

Publicado el 03/02/2017.Leer más »

Andrés Cervantes, entre los galardonados en los premios “Valencianos en la Onda”

Onda Cero entregó este jueves 17 de noviembre sus premios anuales “Valencianos en la Onda” en el Espai Rambleta, y entre los premiados, en el ámbito científico, nuestro oncólogo el Dr. Andrés Cervantes.

Publicado el 18/11/2016.Leer más »

El oncólogo valenciano Andrés Cervantes primer director científico español al frente del Congreso Europeo de Oncología

 Se celebrará en Copenhague, del 7 al 11 de octubre, y en él se dará cita la élite de la oncología médica mundial

Publicado el 04/10/2016.Leer más »

La Unidad de Ensayos Clínicos Fase I de INCLIVA tiene en marcha 21 ensayos con medicamentos oncológicos experimentales

Se realizan ensayos clínicos que prueban la eficacia de un medicamento por primera vez en humanos, también conocidos como “First in human”. Más de 500 pacientes han participado en estos ensayos clínicos oncológicos donde se prueba por primera vez en humanos la eficacia de un medicamento.

 

Publicado el 11/09/2016.Leer más »

Un investigador de INCLIVA coordina la guía clínica europea de consenso para el diagnóstico y tratamiento de los pacientes con cáncer colorrectal

Durante dos días los expertos de la Sociedad Europea de Oncología (ESMO) se reunieron en Zurich para consensuaran los protocolos de la guía que marcará el abordaje de la enfermedad en los próximos años.

 

Publicado el 21/07/2016.Leer más »

Andrés Cervantes dirige el Curso Internacional ESMO-ESO sobre medicina oncológica

Andrés Cervantes dirige el Curso Internacional ESMO-ESO sobre medicina oncológica. El objetivo es captar talento y atraer a futuros especialistas: 60 estudiantes de 27 países.
 

Publicado el 15/07/2016.Leer más »